title: Should oral bisphosphonates be standard of care in women with early breast cancer?
abstract: There is increasing evidence that oral clodronate has important clinical benefits in early breast cancer. Longer-term follow-up data from two out of three randomized studies have shown that adjuvant clodronate improves survival. This article outlines the results of these studies and discusses the potential role for other bisphosphonates, such as ibandronate and zoledronic acid, in the adjuvant treatment of breast cancer.
authors.affiliation: Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada. mark.clemons@sw.ca
authors.forename: Mark
authors.initials: M
authors.lastname: Clemons
authors.forename: Sunil
authors.initials: S
authors.lastname: Verma
mesh_terms: D000963:Antimetabolites / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000517:prevention & control; D017024:Chemotherapy, Adjuvant; D004002:Clodronic Acid / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077268:Pamidronate; D011379:Prognosis; D013534:Survival
chemical_list: D000963:Antimetabolites; D004164:Diphosphonates; D004002:Clodronic Acid; D000077268:Pamidronate